Sign In  |  Register  |  About Daly City  |  Contact Us

Daly City, CA
September 01, 2020 1:20pm
7-Day Forecast | Traffic
  • Search Hotels in Daly City

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

QuBind.com Makes Major Strides in T-Cell Immunotherapy with Revolutionary AI Innovation

By: PRLog

NEW YORK - Dec. 4, 2023 - PRLog -- In just 18 months, the young startup QuBind.com has achieved a remarkable breakthrough in T-cell immunotherapy, developing an advanced AI stack that is set to revolutionize personalized medicine. This significant milestone, reached with predominantly bootstrap funding, support from friends, family, and a strategic investment from a handful general partners in the PE sector, underscores the company's innovative spirit and scientific prowess.

QuBind's AI stack, created on a lean budget, dramatically improves the precision and safety of T-cell therapies. By precisely analyzing both off-target and on-target effects, the technology ensures effective and safe treatments, addressing a major challenge in T-cell immunotherapy. This development is particularly impressive given the company's modest financial resources and rapid timeframe.

Despite its status as a young startup, QuBind.com has quickly attracted the attention of major players in the global healthcare sector. The company is now in advanced talks about M&A and licensing agreements. These discussions are being held confidentially, with the potential acquiring companies utilizing their R&D budgets for potential collaboration.

The interest from these healthcare giants is a testament to the potential of QuBind's AI stack and the company's innovative approach to developing new treatments in the field of immunotherapy. These strategic partnerships could be a game-changer for both QuBind and the future of T-cell therapy.

QuBind's story is a powerful example of entrepreneurial success, showing what can be achieved with a compelling vision, dedicated team, and supportive investors. The company's rapid progress from a bootstrap startup to a key player in healthcare innovation is an inspiration to startups worldwide.

QuBind.com is a dynamic startup leading the way in T-cell immunotherapy. Founded on groundbreaking AI technology, QuBind is reshaping the landscape of patient treatment and advancing the field of personalized medicine, all within an extraordinarily short timeframe and with limited initial capital.

Contact Information: qubind@qubind.com, bd@qubind.com

Photos: (Click photo to enlarge)

Screenshot 2023 06 25 043954 Qubindpng


Source: QuBind Technologies Corp

Read Full Story - QuBind.com Makes Major Strides in T-Cell Immunotherapy with Revolutionary AI Innovation | More news from this source

Press release distribution by PRLog

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 DalyCity.com & California Media Partners, LLC. All rights reserved.